Pier Ramos-Elías

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial

Domenica Lorusso, Yang Xiang, Kosei Hasegawa et al. · The Lancet · 2024 · 349 citations

Medicine, Oncology, Pharmacotherapy +13

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial

Domenica Lorusso, Yang Xiang, Kosei Hasegawa et al. · The Lancet · 2024 · 161 citations

Medicine, Oncology, Pharmacotherapy +12

Primary breast cancer cell culture yields intra-tumor heterogeneous subpopulations expressing exclusive patterns of receptor tyrosine kinases

José Esparza‐López, Pier Ramos-Elías, Andrea Castro‐Sánchez et al. · BMC Cancer · 2016 · 16 citations · Full text

Medicine, Cancer Biology, Oncology +15

Change in therapeutic management after the EndoPredict assay in a prospective decision impact study of Mexican premenopausal breast cancer patients

Cynthia Villarreal‐Garza, Edna Anakarenn Lopez-Martinez, Zuratzi Deneken-Hernández et al. · PLoS ONE · 2020 · 10 citations · Full text

Medicine, Oncology, Breast Oncology +14